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Abstract
NURR1/NR4A2 is an orphan nuclear receptor that is critical for the development and maintenance of mesencephalic
dopaminergic neurons and regulates transcription of genes involved in the function of dopaminergic neurons directly via
specific NGFI-B response elements (NBRE).and substantial data support a possible role of Nurr1 in the pathogenesis of
Parkinson’s disease (PD). Here we show that Nurr1 is degraded by the ubiquitin-proteasome pathway and determined that
N-terminal region (a.a 1–31) of Nurr1 is essential for an efficient targeting of Nurr1 to degradation in the cell. Nurr1 D1–31
has a much longer half-life, and as a consequence its steady-state protein levels were higher, than full-length Nurr1 in the
cell. Nurr1 D1–31 was as potent as Nurr1 full length in transcriptional luciferase reporter assays after normalization with the
corresponding steady-state protein expression levels, either in trans-activation of NBRE or trans-repression of iNOS
(inducible NO synthase) reporters. These results suggest that Nurr1 D1–31, because of longer persistence in the cell, can be
a good candidate for gene and cell therapies in the treatment of PD.
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Introduction
NURR1 (Nur-related factor 1, NR4A2/NOT1/RNR-1/HZF-
3/TINUR) gene, a member of nuclear receptor superfamily [1],
[2], is an orphan nuclear receptor that behaves as a transcriptional
activator in the central nervous system, and is required for the
development of mesencephalic dopamine (mesDA) neurons. It is
highly expressed in mesDA neurons during development and
throughout adulthood [3] [4] [5]. In mice lacking NURR1,
mesencephalic precursors fail to undergo terminal differentiation
and adopt a mature dopaminergic phenotype, dying as develop-
ment progresses [6], [7], [8]. Nurr1 is implicated in the
differentiation, survival, connectivity and migration of mesDA
neurons. Importantly, Nurr1 directly induces transcription of
tyrosine hydroxylase, the rate limiting enzyme in the synthesis of
dopamine [9] [10] [11], as well as other important dopaminergic
markers, including the dopamine transporter and vesicular
monoamine transporter 2 [12]. Nurr1 is also required for
maintenance of maturing and adult dopaminergic neurons [13].
Nurr1 contains N- and C-terminal activation domains (AF-1 and
AF-2, respectively) thought to regulate its transcriptional activity
[14], [15], [16], [17]. Nurr1 transcriptional activity is positively
regulated by mitogen-activated protein kinase (ERK1/2, ERK5)
signalling via the N-terminal AF-1 region, and ERK1,2/ERK5
phosphorylation sites have been identified proximal to the AF-1
core of Nurr1 [18] [16] [19] [20] [21] and negatively regulated by
LIMK1 [21]. Nurr1 also functions as a trans-repressor of pro-
inflammatory gene promoters in macrophages, microglia and
astrocytes by recruiting CoREST corepressor complex [22].
The important role that Nurr1 plays in dopaminergic neurons
has been underscored by the identification of several changes in its
gene that are associated with Parkinson’s disease (PD). Two
monoallelic mutations in the 59 region of Nurr1 gene (c.-
291delinsT and c.-245T.G) have been shown to be associated
with PD, those mutations reduced the expression of Nurr1 [23], a
homozygous 7048G7049 polymorphism was found in intron 6 of
the Nurr1 gene in association with PD [24], a missense mutation
(S125C) in Nurr1 has been described in a PD patient [25] and a
single base substitution in the 59-UTR (c.-309C.T) correlated
with a decrease in Nurr1 mRNA expression has also been
described in PD patients [26]. Furthermore, Nurr1 expression is
reduced in neurons with pathological signs in brains of PD patients
[27] and a decrease in Nurr1 activity is observed in peripheral
blood lymphocytes of PD patients [28]. As a consequence, it has
been suggested that Nurr1 can be a potential target to develop
novel therapeutic strategies in PD aimed to enhance the survival of
mesDA neurons to stress [15], [29], [30].
We have approached the study of the degradation pathway of
Nurr1 because its importance in the maintenance of the
dopaminergic phenotype, its implication in PD and its role as a
protector for adult dopaminergic neurons. Previously it has been
shown that Nurr1 is degraded by the ubiquitin proteasome
pathway [31]. Here we confirmed that Nurr1 is degraded by the
PLOS ONE | www.plosone.org 1 February 2013 | Volume 8 | Issue 2 | e55999
proteasome pathway and this degradation is dependent of the N-
terminal region of Nurr1 (aminoacids 1 to 31). Deletion of this N-
terminal region of Nurr1 produce a rather stable Nurr1 protein
with full capabilities as transcription factor, accordingly Nurr1 D1–
31 construct could be an excellent candidate for its use in genetic
and cell therapeutic strategies for PD patients.
Materials and Methods
Recombinant DNA constructs
DNA constructs for expression of mouse Nurr1 and Flag-Nurr1
were generated from a mouse Nurr1 cDNAs and cloned into
pcDNA3.1 (Zeo+) either untagged or Flag-tagged in the N-
terminus. The construct Nurr1 1–337 was produced by PCR
introducing a stop codon at position 338 of mouse Nurr1 sequence
using the following oligonucleotides: 59Nurr1 1–337 59-
CGCACGGACAGTTAAAAAGGCCGGAGAGG-39 and
39Nurr1 1–337 59-CCTCTCCGGCCTTTTTAACTGTCCG-
TGCG-39. The constructs Nurr1 D163–187, Nurr1 D163–217
and Nurr1 D163–247 internal deletion mutants were obtained by
PCR from mouse Nurr1 construct in pcDNA 3.1 by substituting
the NdeI/XhoI cassette of Nurr1 (NdeI cleaves after nucleotide
481, leaving in aminoacids 1–162) with the products of amplifi-
cation (digested with NdeI/XhoI) of mouse Nurr1 obtained with
the following oligonucleotides:
59NdeI-Nurr1 D163–187 59-GACGCATATGTCTAGCTGC-
CAGATGCGCTTCGAC-39, 59NdeI-Nurr1 D163–217 59-
GCGACATATGTTCGCCGTGCCCAACCC-39, 59NdeI-
Nurr1 D163–247 59-GCACGCATATGTCGCAGTTGCTTGA-
CAC-39 and a common reverse primer 39XhoI-Nurr1 59-
AGCGCTCGAGTTAGAAAGGTAAGGTGTCCAGG-39. The
constructs Nurr1 D1–96, Nurr1 D1–161 and Nurr1 D1–262 N-
terminal deletion mutants were obtained from mouse Nurr1
construct in pcDNA3.1 and the following oligonucleotides:
59Nurr1 D1–96 59-CGAAAGCTTATGCACAATACCAGCAA-
CACAGCC-39, 59Nurr1 D1–161 59-CCGAAGCTTATGATC-
GAGGCAGAGGAAGAC-39, 59Nurr1 D1–262 59-GGCAAG-
CTTATGTGCGCTGTTTGCGGTGACAACG-39 and the
common reverse primer 39XhoI-Nurr1. The constructs Nurr1
D1–80, Nurr1 D1–63, Nurr1 D1–43 and Nurr1 D1–31, N-
terminal deletion mutants were obtained by PCR from mouse
Nurr1 construct in pcDNA3.1 with the following oligonucleotides:
59Nurr1 D1–80 59-GCGTAGATCTATGCCCCTGTCCGGA-
CAGC-39, 59Nurr1 D1–63 59-GCGTAGATCTATGGACAAC-
TACAGC-39, 9Nurr1 D1–43 59-GCGTAGATCTATGGACCT-
CACCAAC-39, 59Nurr1 D1–31 59-GCCTAGATCTATGGATT-
TCTTAACTCC-39 and the common reverse primer 39XhoI-
Nurr1. Introduction of the point mutation S125C into Nurr1
coding sequence was obtained by site-directed mutagenesis using
the Stratagene ‘‘Quick-base change’’ method. Nurr1 triple Pro/
Ala mutant (Nurr1 P2/12/17 A) was obtained by amplification
from wild type Nurr1 with the following primers:: 59Nurr1 P2/12/
17A: 59-GCGTAGATCTATGGCTTGTGTTCAGGCGCAG-
TATGGGTCCTCGGCTCAAGGAGCCAGCGCCGCTTCTC-
AGAGC-39 and 39 Xho reverse primer: 59-AGCGCTCGAGT-
TAGAAAGGTAAGGTGTCCAGG-39, fragment was digested
with BglII/XhoI and ligated into pcDNA3.1 (Zeo+) digested with
the same restriction enzymes. All constructs were completely
sequenced by automatic DNA sequencing
Figure 1. Degradation of endogenous Nurr1 in PC12 cells and ectopically expressed Nurr1 in HeLa cells. (A) PC12 cells were treated
with CHX in the absence or in the presence of Lactacystin (Lacta) for the times indicated and cell extracts analyzed by immunoblot with anti-Nurr1
antibodies. (B, D and F) HeLa cells were transiently transfected with full-length Nurr1, N-terminal flag-tagged Nurr1 or Nurr1 1–337 as indicated, after
transfection cells were treated with CHX in the absence or in the presence of Lactacystin (Lacta) for the times indicated and cell extracts analyzed by
immunoblot with anti-Nurr1 antibodies (B and D). Protein loading control was assessed by immunobloting with anti-tubulin antibodies. (C and E)
Graphs show the quantification of immunoblots, and results are expressed as means 6 s. e. m. from three different experiments of the indicated
Nurr1 protein constructs. F, transfected cells were analyzed by indirect immunofluorescence with anti-Nurr1 antibodies (red channel), counterstained
for nuclei with DAPI (blue channel) and imaging by confocal microscopy for subcellular localization of Nurr1.
doi:10.1371/journal.pone.0055999.g001
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Study of endogenous Nurr1 degradation in PC12 cells
Rat PC12 cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM, Gibco BRL) supplemented with 10% horse
serum (Gibco BRL), 5% foetal bovine serum (Gibco BRL) and
100 mg/mL gentamycin, at 37uC and 5% CO2 in P60 Petri dishes.
Cells were treated with 25 mg/ml cycloheximide (CHX) in the
absence or in the presence of 10 mM lactacystin for the times
indicated up to 12 h. After the treatments, cells were washed in
phosphate-buffered saline (PBS) and lysed in 200 ml of lysis buffer
per well plate (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1%
NP40, 2% SDS, 1% deoxycholate, 20 mM leupeptin, 10 mg/ml
pepstatin, 1 mM PMSF); Cell extracts were sonicated for 10 min
on ice, centrifuged at 140006g for 30 min at 4uC and the
supernatants were used to measure total protein concentration by
BCA protein assay kit (Thermo Scientific-Pierce). Total proteins
(50 mg) were separated onto 10% SDS-PAGE gels and transferred
to nitrocellulose membrane for Western immunoblot analysis.
Membranes were blocked with TTBS (50 mM Tris-HCl pH 7.5,
150 mM NaCl, 0.1% Tween-20) with 3% BSA o.n. The blots
were then probed with anti-Nurr1 antibodies 1:1000 (Santa Cruz
Biotechnology, Sc-990 or Sc-991 directed against the C-terminal
and N-terminal region of Nurr1, respectively) and anti-tubulin
(1:1000, DM1A, Sigma) as loading control. Signals from the
primary antibodies were amplified using species-specific antibodies
to rabbit or mouse IgG conjugated with horseradish peroxidase
(Bio-Rad). Immunoblots were developed by direct capture of
chemiluminescence with DNR MF-ChemiBIS 3.2 Bio-Imaging
System and quantification with Totallab TL100 software. Results
are expressed as mean 6 s.e.m. for a minimal number of three
independent experiments.
Studies of ectopically expressed Nurr1 degradation in
HeLa cells
HeLa cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM, Gibco BRL) supplemented with 10% foetal bovine
serum (Sigma-Aldrich) and 100 mg/mL gentamycin, at 37uC and
5% CO2. HeLa cells were plated at 3610
5cells/well in 6-well
plates and transfected with Lipofectamine (Invitrogen). Transfect-
ed cells were treated with the protein synthesis inhibitor CHX
(25 mg/ml) for the times indicated; 10 mM Lactacystin, or 50 nM
Leptomycin B was added where indicated. Transfected cells were
processed as described above for PC12 cells and analyzed by
immunoblot using the following primary antibodies: anti-Nurr1
(1:1000, Santa Cruz Biotechnology Sc-990 and Sc-991), or anti-
tubulin antibodies (1:1000, Sigma, DM1A) as control for protein
loading. Values reported are means 6 s.e.m. from three
independent experiments.
For the study of Nurr-1 ubiquitylation, cells were co-transfected
with HA-tagged ubiquitin construct (provided by Dr. Dirk
Bohmann, Department of Biomedical Genetics, University of
Rochester Medical Center, Rochester, USA).plus Nurr1 full-
length or Nurr1 D1–31 deletion construct. Transfected cells (36 h
after transfection) were incubated in the presence or in the absence
Figure 2. Effect of treatment of cells with Leptomycin B on the
degradation of Nurr1. HeLa cells were transiently transfected with
full-length Nurr1, after transfection cells were treated with CHX in the
absence or in the presence of Lactacystin (Lacta) or Leptomycin B for
the times indicated and cell extracts analyzed by immunoblot with anti-
Nurr1 antibodies Protein loading control was assessed by immunoblot-
ing with anti-tubulin antibodies. Graphs show the quantification of
immunoblots, and results are expressed as means 6 s. e. m. from three
different experiments.
doi:10.1371/journal.pone.0055999.g002
Figure 3. Effect of internal deletions within the N-terminal
region of Nurr1 in its degradation. HeLa cells were transiently
transfected with full-length Nurr1, Nurr1 D163–187, D163–217 and
D163–249 as indicated, after transfection cells were treated with CHX in
the absence or in the presence of Lactacystin (Lacta) for the times
indicated and cell extracts analyzed by immunoblot with anti-Nurr1
antibodies (A). Protein loading control was assessed by immunobloting
with anti-tubulin antibodies (A). (B) Graph shows the quantification of
immunoblots, and results are expressed as means 6 s. e. m. from three
different experiments of the indicated Nurr1 protein constructs. (C) Cells
were also analyzed by indirect immunofluorescence with anti-Nurr1
antibodies (red channel), counterstained for nuclei with DAPI (blue
channel) and imaging by confocal microscopy for Nurr-1 subcellular
localization.
doi:10.1371/journal.pone.0055999.g003
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of 10 mM lactacystin for 12 h. Cells were lysed in 50 mM Tris-
HCl pH 7.5, 150 mM NaCl, 0.5% NP40, 20 mM leupeptin,
10 mg/ml pepstatin, 1 mM PMSF and the clear lysates were
immunoprecipitated with anti HA-antibody (Roche) previously
coupled to protein G-Sepharose (GE-HealthCare). The immuno-
precipitates were loaded onto 10% SDS-PAGE, transferred to
nitrocellulose, and developed with anti-Nurr1 antibody (1:1000,
Sc-990, Santa Cruz Biotechnology).
To study Nurr1 mediated transactivation, HeLa cells were
transfected with pcDNA Nurr1 or pcDNA Nurr1 D1–31 and D1–
80, the reporter plasmid 3xNBRE-tk-Luc containing 3 copies of
the Nurr1-responsive element (provided by Dr. Thomas Perl-
mann, Ludwig Institute for Cancer Research Ltd., Stockholm,
Sweden) and Renilla as a reporter control. Luciferase activity was
assayed with the Dual-Luciferase reporter assay system from
Promega according to the manufacturer’s instructions. For the
studies of Nurr-1 trans-repression, RAW 264.7 macrophage cell
line was grown in RPMI plus 15% fetal bovine serum and
transfected by nucleofection (Nucleofector, Lonza AG) as per
manufacturer’s protocol with pcDNA (mock), pcDNA Nurr1 or
pcDNA Nurr1 D1–31, the reporter plasmid iNOS (inducible NO
synthase) murine-luciferase piNOSm-luc [32] provided by Dr.
Manuel Fresno, Centro de Biologı´a Molecular Severo Ochoa,
Madrid, Spain) and Renilla as reporter control. Transfected RAW
264.7 cells were stimulated with bacterial lipopolysaccharide (LPS,
Sigma) at 0.1 mg/ml for 8 h and luciferase assays were performed
as described above. For both type of transcriptional assays results
are expressed as means6 s.e.m. for the quotient of the activities of
firefly and Renilla luciferase.
Immunofluorescence and confocal microscopy
Cells were grown on coverslips and 36 h post-transfection
coverslips were washed 3 times with cold PBS, fixed with 4%
paraformaldehyde in PBS for 20 min and permeabilized and
blocked with PBS, 1% Triton X-100 containing 3% BSA for 1 h
at room temperature. Primary anti-Nurr1 antibody (1:1000, Santa
Cruz Biotechnology Sc-990) was added in the blocking solution
without Triton X-100, and incubated for 2 h at room tempera-
ture. After washing 5 times (each for 5 min) with PBS, coverslips
were incubated with Alexa Fluor 488 conjugated anti-mouse
antibody (1:500 dilution) for 1 h, washed again 5 times with PBS.
For nuclear visualization 49,6-diamidino-2-phenylindole (DAPI,
5 mg/ml) was added in the first wash with PBS. Coverslips were
finally mounted with ProLong for confocal microscopy observa-
Figure 4. Effect of the deletions from the N-terminal of Nurr1 on its degradation. HeLa cells were transiently transfected with full-length
Nurr1, D1–262, D1–161 and D1–96 (A) or Nurr1 D1–80, D1–63, D1–43, and D1–31 (C) as indicated, after transfection cells were treated with CHX in the
absence or in the presence of Lactacystin (Lacta) for the times indicated and cell extracts analyzed by immunoblot with anti-Nurr1 antibodies (A and
C). Protein loading control was assessed by immunobloting with anti-tubulin antibodies. (B and D) Graphs show the quantification of immunoblots,
and results are expressed as means 6 s. e. m. from three different experiments of the indicated Nurr1 protein constructs. (E) Cells were also analyzed
by indirect immunofluorescence with anti-Nurr1 antibodies (red channel), counterstained for nuclei with DAPI (blue channel) and imaging by
confocal microscopy for Nurr-1 subcellular localization of the different Nurr1 constructs as indicated.
doi:10.1371/journal.pone.0055999.g004
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tion in a laser scanning microscope (Carl Zeiss LSM-510). Images
were captured with the same settings for each set of experiments.
Controls, omission of primary or secondary antibodies, revealed
no fluorescence.
Results
Proteasomal degradation of Nurr1
To begin the study of the mechanism of Nurr1 degradation, we
analyzed the degradation of endogenous Nurr1 in PC12 cells by
treatment of cells with CHX. As shown in Fig. 1A and C,
endogenous Nurr1 in PC12 cells is degraded with an apparent
half-life of 3–4 h and the degradation was prevented by co-
treatment with lactacystin, a specific and irreversible proteasome
inhibitor. Next similar experiments were done by transfection of
Nurr1 constructs in HeLa cells. Results presented in Fig. 1B and C
shows that the half-life of transfected untagged Nurr1 shows
similar kinetics as the endogenous Nurr1 in PC12 cells, and again
the degradation was inhibited by co-treatment with lactacystin. To
facilitate the study of the regions of Nurr1 that may be implicated
in its degradation, we thought convenient to use a tagged version
of Nurr1. We made a N-terminal flag-tagged version of Nurr1 that
was transfected in HeLa cells and its half-life estimated by CHX
treatment. As shown in Fig. 1B and C, the N-terminal flag-tagged
Nurr1 has a longer half-life (12–14 h) than the untagged Nurr1 (3–
4 h). All these results show that Nurr1 is degraded by the
proteasome pathway with similar half-lives in cells of neuronal
origin (PC12) and non-neuronal cells (HeLa) and suggested that
the N-terminal region of Nurr1 may be important for degradation,
because tagging Nurr1 at its N-terminal region produced an
inhibition of its degradation rate in the cell. Accordingly, a N-
terminal 1–337 Nurr1 construct was obtained. Results presented
in Fig. 1D and E shows that a Nurr1 protein construct comprising
aminoacids 1–337 was degraded with similar kinetics to the full
length Nurr1. Note that all these Nurr1 constructs showed a
nuclear localization by immunofluorescence confocal imaging
(Fig. 1F), as the predicted nuclear localization signal of mouse
Nurr1 is located within aminoacids 309-KRRRNR-314. Further-
more, inhibition of nuclear export by treatment of cells with
Leptomycin B did not affect the rate of degradation of Nurr1
(Fig. 2). Taken together, these results indicate that the degradation
of Nurr1 is mainly taken place in the cell nucleus.
Delineation of the N-terminal region that targets Nurr1
for proteasomal degradation
The region of mouse Nurr1 from aminoacids 1–351 contains
the AF-1 transactivation region of Nurr1, being the minimal
transactivating region restricted to aminoacids 1–122 and the core
transactivation sequence located between aminoacids 52–82 [16].
This region also contains the nuclear localization signal of Nurr1
309–314 as mentioned above, several phosphorylation sites (S126,
T132 and T185) by MAPK/[16,18] [20] and the region for the
interaction with ERK1/2, ERK5 and LIMK1 that regulate Nurr1
transcriptional activity [21]. To define more precisely the sequence
within the N-terminal region of Nurr1 required for targeting
Nurr1 to proteasomal degradation, several deletion constructs
were made from the convenient NdeI site of mouse Nurr1
corresponding to Met 162 and moving downstream, in all cases
keeping the nuclear localization signal of Nurr-1. As shown in
Fig. 3A and B, Nurr1 D163–187, D163–217, and D163–249 were
degraded as efficiently as Nurr1 full-length in transfected cells,
indicating that aminoacids 163–249 of the N-terminal region of
Nurr1 did not seem to harbor the putative proteasomal targeting
sequences of Nurr1, and as predicted those deletion constructs
were located in the cell nucleus (Fig. 3C). Accordingly, we turned
to the N-terminal portion and made three deletions D1–262, D1–
161 and D1–96. Transfection of these N-terminal constructs into
HeLa cells (Fig. 4A and B) showed that any of the deletions greatly
diminished the degradation rate of Nurr1, being all those
constructs also localized into the cell nucleus (Fig. 4E). These
results clearly suggested that the region of Nurr1 spanning from
aminoacid 1–96 contains the linear sequence within Nurr1 that is
required for its proteasomal degradation. To further map the
sequence within this N-terminal region, several deletion constructs
from Met1 to 80, 63, 43, and 31 were generated. As shown in
Fig. 4C and D all those deletions markedly reduced the
degradation of the corresponding Nurr1 constructs, indicating
that the minimal region required for efficient Nurr1 degradation
seems to be present in the N-terminal region aminoacids 1–31 of
the Nurr1 protein and again all of these deletion constructs
localized in the cell nucleus (Fig. 4E).
Ubiquitylation of Nurr1
To check the ubiquitylation of Nurr1 and Nurr1 D1–31, HeLa
cells were transiently co-transfected with those vectors and an HA-
tagged ubiquitin expression vector. Ubiquitylated proteins were
immunoprecipitated from solubilized cells using antibodies to the
HA epitope and then separated by SDS-PAGE and immuno-
blotted with anti-Nurr1 antibodies. Results (Fig. 5A) showed that
both Nurr1 and Nurr1 D1–31 are poly-ubiquitylated and those
Figure 5. Ubquitylation of Nurr1 and Nurr1 D1–31. HeLa cells
were co-transfected with Nurr1 full length or D1–31 and HA-ubiquitin
and either untreated or treated with lactacystin (Lacta) as indicated, cell
extracts were immunoprecipatated with anti-HA antibodies, analyzed
by SDS-PAGE and immunoblotted with anti-Nurr1 antibodies (A). (B)
Direct immunoblot with anti-Nurr1 antibodies of 1/10 of the amount of
total cell extracts (shorter exposure than the upper panel) used for
immunoprecipitation experiments shown in the upper panel. Protein
loading control was assessed by immunobloting with anti-tubulin
antibodies.
doi:10.1371/journal.pone.0055999.g005
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species accumulated when cells are treated with lactacystin. Note
also that the steady state expression levels of Nurr1 D1–31 are
higher than those of Nurr1 full length (Fig. 5B, input), as expected
because of its longer half-life.
Transcriptional transactivation and trans-repression by
Nurr1 and N-terminal deletion mutants
Nurr1 binds the consensus NBRE site (AAAGGTCA) that is
present in the promoter region of genes that are regulated by this
nuclear receptor [9] [10] [11] [12]. As a consequence, we decided
to study if the N-terminal Nurr1 deletion mutants can activate a
3xNBRE luciferase reporter construct using transient transfection
assays. To that end, we performed co-transfections experiments of
the NRBE firefly luciferase construct (with Renilla luciferase as a
control) and different doses of Nurr1 full length and two deletion
mutants Nurr1 D1–80 and Nurr1 D1–31. These experiments
showed that different DNA concentrations of Nurr1 and Nurr1
D1–31 produced a dose-dependent activation of NBRE luciferase
reporter (Fig. 6A), while Nurr1 D1–80 was defective in this
transactivation assay. The degree of activation mirrored the
increase observed in the amounts of Nurr1 protein levels (Fig. 6B).
Accordingly, when the activation of the NRBE-luciferase reporter
was corrected for the levels of expression of the respective Nurr1
proteins, the relative potency of Nurr1 full-length and Nurr1 D1–
31 was not significantly different (Fig. 6C). In contrast, Nurr1 D1–
80 that has also higher protein steady-state levels than Nurr1 full-
length is completely ineffective in transactivation, as expected
because this deletion mutant removes most of the AF-1
transactivation domain (aa 1–122) of Nurr1 [16].
Nurr-1 has also been described to act as a trans-repressor
recruiting the CoREST corepressor complex that produces the
inhibition of pro-inflamatory responses in astrocytes, microglia
and macrophages [22]. Accordingly, it was interesting to study the
behavior of Nurr1 D1–31 deletion mutant in this context. As
shown in Fig. 6 D and E, the stimulation of an iNos luciferase
reporter in RAW264.7 (a macrophage cell line) by LPS can be
prevented by expression of Nurr1 as described previously [22],
and the deletion mutant D1–31 has also similar effects as wild-type
Nurr1. These results showed that deletion of the first 31
aminoacids of Nurr1 did not modify its ability to promote either
transcriptional activation or trans-repression, behaving like Nurr1
full length, and its better performance can be explained by its
decreased rate of degradation that resulted in an increase in the
steady-state levels of the Nurr1 D1–31 respect to the full-length
Nurr1.
Discussion
The results presented in the present report show that the Nurr1
degradation is mediated by the ubiquitin-proteasome pathway, as
it is inhibited by specific proteasome inhibitors and polyubiqui-
tylated at its subcellular nuclear localization. The lysosomal
pathway of degradation does not seem to be involved in Nurr1
degradation, as treatment of cells with leupeptin, E64b or
chloroquine did not affect the steady-state levels of Nurr1 (data
not shown). We have shown that one main determinant for
proteasomal degradation of Nurr1 is located at the N-terminal
region comprising aminoacids 1–31 that has no structural motives
and scores very poorly as a possible PEST region [33]; and its
deletion must not alter significantly its structure as it did not affect
its localization in the nucleus or its function as a transcriptional
regulator. Further experiments to precisely define the aminoacids
responsible may not be an easy task because this N-terminal region
may tolerate substantial aminoacid changes without affecting
Figure 6. Transcriptional assays of Nurr1 and N-terminal deletion mutants. HeLa cells were cotransfected with empty pcDNA (0) or
different doses of DNA of Nurr1 full length, Nurr1 D1–80 or Nurr1 D1–30 and constant amounts of DNA of NRBE firefly (400 ng) and Renilla luciferase
(100 ng) reporters. (A) Graph showing the DNA dose response curve of the quotient of activities of firefly/Renilla luciferase (fold). (B) Immunoblot
analysis with anti-Nurr1 antibodies of the DNA dose dependent expression of the different Nurr1 constructs transfected in HeLa cells, as indicated. (C)
Graph showing the DNA dose response curve of the quotient of activities of firefly/Renilla luciferase divided by the amount of Nurr1 protein
expression levels as judged by immunoblotting (fold). (D) RAW 264.7 cells were transfected with empty pcDNA (0), pcDNA Nurr1 or Nurr1 D1–31, and
constant mounts of the reporter plasmid iNOS luciferase (400 ng) and Renilla (100 ng) as control. Cells were stimulated with bacterial LPS for 8 h and
collected for Western immunblotting with anti-Nurr1 and anti-tubulin antibodies, as protein control loading (D) or for luciferase assays. (E) Graph
shows the quotient of activities of firefly/Renilla luciferase divided by the amount of Nurr1 protein expression levels as judged by immunoblotting
(fold).results are expressed as means 6 s. e. m. from three different experiments.
doi:10.1371/journal.pone.0055999.g006
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Nurr1 degradation. In fact, in an initial attempt to experimentally
address this issue, we generated a triple point mutant where
prolines (alpha-helix disrupter aminoacid) at positions 2, 12 and 17
were changed to Ala. This triple Pro/Ala Nurr1 mutant had a
half-life not significantly different from the Nurr1 wild type (data
not shown). Nevertheless, Nurr1 D1–31 is still poly-ubiquitylated
and degraded while much less efficiently than Nurr1 wild type.
The exact mechanism responsible of its reduced degradation rate
remains to be determined. Nurr1 D1–31 may be either a less good
substrate for the E3 ligase involved in the ubiquitylation of Nurr1
(decrease recognition or insufficient extension of the covalently
bound poly-ubiquitin); and/or the poly-ubiquitylated Nurr1 D1–
31 may be ineffectively recognized by the 19S proteasomal
complex and/or ineffectively translocated to the catalytic chamber
of the 20S proteasomal complex for degradation.
Nurr1 D1–31 is as potent as Nurr1 full-length in transactivation
and trans-repression of luciferase reporter constructs, when
corrected for the protein expression levels of both proteins, as
Nurr1 D1–31 steady-state protein levels are higher than the levels
of Nurr1 full length due to its longer half-life in the cell. These
results are in agreement with the fact that the region 1–31 of
Nurr1 is closed, but do not overlap, with the core region of the AF-
1 transactivation domain of Nurr1, aminoacids 52–82 [16] and
also will not interfere with ERK1/2 and ERK5 and LIMK1, as
deletion of a.a 1–52 of Nurr11 does not affect the binding of any of
these kinases that regulate Nurr1 activity [21]. The regions
responsible of Nurr1 trans-repressor activity remains to be fully
characterized. It is known that trans-repression of Nurr1 is
suppressed by overexpression of Nurr1 DNA binding domain
(DBD) indicating that the DBD is required for the interaction of
Nurr1 with CoREST [22]. Certainly, the DBD of Nurr1 is not
affected by the N-terminal 1–31 deletion of Nurr1, and as a
consequence Nurr1 D1–31 behaves similar in trans-repression
assays (shown here) as the wild type Nurr1.
The report that Nurr1 phosphorylation by AKT at Ser347
promotes its degradation [31] make us to repeat those experi-
ments, and we found that the mutant Nurr1 S347A has the same
half-life as the wild type Nurr1 (data not shown), consistently with
the results presented here that the main determinant of Nurr1
degradation is located within aminoacids 1–31 of the N-terminal
region of Nurr1.This apparent conflict of results may be due in
part to the fact that Jo et al. [31] used for their studies a flag-tagged
version of Nurr1. Tagging of Nurr1 at its N-terminus with a flag
epitope, as shown here, resulted in an inhibition of its degradation
rate in the cell by the ubiquitin-proteasome pathway (Fig. 1B),
accordingly their results may not be relevant for the actual
mechanism of degradation of the natural untagged Nurr1.
The presumptive role of Nurr1 in PD pathogenesis made us also
to explore the possible effect of the mutation S125C that has been
shown to be present in a PD patient [25] in Nurr1 degradation
and consistently with the results presented here, the missense
mutation that is located further downstream of the core N-
terminal (aa1–31) did not affect the degradation rate of Nurr1
(data not shown), while this mutant has been reported to have a
markedly reduced transactivation-activity [34]. A recent report
also links Nurr1 with alpha-synuclein, a key protein in PD
pathogenesis, and describes that alpha-synuclein over-expression
by an unidentified mechanism promote Nurr1 degradation [35]
linking mesencephalic Dopamine (mesDA) neurons maintenance
and survival by Nurr1 and the expression levels of alpha-synuclein.
We have studied the degradation of Nurr1 either by co-tranfection
of alpha-synuclein and Nurr1 into HeLa cells, or by transfection of
Nurr1 into N2a cells and N2a cells stably expressing alpha-
synuclein [36] and we have found no effect of alpha-synuclein
expression in the half-life of Nurr1 (3–4 h). In this context, recently
published results using over-expression of alpha-synuclein in
mesDA neurons also show a decrease in the expression of Nurr1
and Nurr1 downstream regulated genes, but this effect is mainly
due to transcriptional down-regulation of Nurr1 by over-expres-
sion of alpha-synuclein [37].
The identification of the N-terminal region (a.a 1–31) in Nurr1
allowed us the production of a variant form of Nurr1 where that
sequence was deleted and that was a rather stable protein in the
cell and works very efficiently in promoting transactivation and
trans-repression. Accordingly, the Nurr1 D1–31 becomes an ideal
candidate to be used for direct gene transfer or transduction in
cell-based therapies for the treatment of PD patients, because this
construct keeps the main mechanisms of regulation of Nurr1
transactivation [18] [16] [19] [20] [21] and trans-repression
known to be involved in tis anti-inflammatory properties [22], but
it has a longer half-life than natural Nurr1: Nevertheless, it may be
necessary to manipulate the expression levels of Nurr1 in neural
stem/progenitor cells to mimic its expression during development
of midbrain dopamine neurons in order to obtain good yields of
neuronal DA cells for transplantation [38].
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